Total Payments
$1,240
2024 Payments
$370.83
Companies
12
Transactions
20
Medicare Patients
4,167
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$1,240 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,240 | 20 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GE HEALTHCARE | $362.89 | 4 | $0 (2024) |
| GENZYME CORPORATION | $329.70 | 4 | $0 (2017) |
| PFIZER INC. | $127.96 | 2 | $0 (2024) |
| Bayer HealthCare Pharmaceuticals Inc. | $119.89 | 1 | $0 (2021) |
| Blue Earth Diagnostics Limited | $78.77 | 1 | $0 (2024) |
| Eisai Inc. | $50.00 | 1 | $0 (2020) |
| Lilly USA, LLC | $49.36 | 1 | $0 (2023) |
| Astellas Pharma US Inc | $40.59 | 2 | $0 (2019) |
| bioMerieux Inc | $27.42 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $20.00 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $370.83 | 6 | GE HEALTHCARE ($254.16) |
| 2023 | $76.78 | 2 | Lilly USA, LLC ($49.36) |
| 2021 | $119.89 | 1 | Bayer HealthCare Pharmaceuticals Inc. ($119.89) |
| 2020 | $50.00 | 1 | Eisai Inc. ($50.00) |
| 2019 | $164.27 | 4 | PFIZER INC. ($108.57) |
| 2017 | $458.48 | 6 | GENZYME CORPORATION ($329.70) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/04/2024 | GE HEALTHCARE | — | Food and Beverage | In-kind items and services | $29.18 | General |
| 07/18/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/02/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $18.51 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 01/24/2024 | GE HEALTHCARE | — | Food and Beverage | In-kind items and services | $143.19 | General |
| 01/24/2024 | GE HEALTHCARE | — | Food and Beverage | In-kind items and services | $81.79 | General |
| 01/19/2024 | Blue Earth Diagnostics Limited | POSLUMA (Drug) | Food and Beverage | In-kind items and services | $78.77 | General |
| Category: Diagnostic Imaging | ||||||
| 06/25/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $49.36 | General |
| 05/17/2023 | bioMerieux Inc | — | Food and Beverage | In-kind items and services | $27.42 | General |
| 12/09/2021 | Bayer HealthCare Pharmaceuticals Inc. | Xofigo (Drug) | Food and Beverage | In-kind items and services | $119.89 | General |
| Category: Oncology | ||||||
| 01/25/2020 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| 12/09/2019 | Astellas Pharma US Inc | LEXISCAN (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: CARDIOLOGY | ||||||
| 06/25/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/01/2019 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $108.57 | General |
| 02/28/2019 | Siemens Medical Solutions USA, Inc. | SPECT Symiba Intevo (Device) | Food and Beverage | In-kind items and services | $15.16 | General |
| Category: MI - Nuclear Medicine (incl. PETNET & MIBR) | ||||||
| 12/14/2017 | GE HEALTHCARE | DISCOVERY (Device) | Food and Beverage | Cash or cash equivalent | $108.73 | General |
| Category: MOLECULAR IMAGING & COMPUTED TOMOGRAPHY | ||||||
| 07/19/2017 | GENZYME CORPORATION | DISEASE STATE (Drug) | Food and Beverage | In-kind items and services | $96.59 | General |
| 06/13/2017 | GENZYME CORPORATION | THYROGEN (Drug) | Food and Beverage | In-kind items and services | $110.86 | General |
| Category: RARE DISEASE METABOLIC | ||||||
| 03/10/2017 | Astellas Pharma US Inc | Lexiscan (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Cardiology | ||||||
| 03/01/2017 | GENZYME CORPORATION | THYROGEN (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: RARE DISEASE METABOLIC | ||||||
| 01/05/2017 | GENZYME CORPORATION | THYROGEN (Drug) | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: RARE DISEASE METABOLIC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,080 | 1,325 | $1.4M | $404,131 |
| 2022 | 17 | 1,023 | 1,106 | $1.1M | $255,338 |
| 2021 | 19 | 1,076 | 1,176 | $957,300 | $227,649 |
| 2020 | 22 | 988 | 1,047 | $686,205 | $143,130 |
Total Patients
4,167
Total Services
4,654
Medicare Billing
$1.0M
Procedure Codes
88
All Medicare Procedures & Services
88 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 147 | 172 | $883,288 | $206,211 | 23.3% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 20 | 189 | $149,310 | $92,292 | 61.8% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 136 | 160 | $95,700 | $65,805 | 68.8% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Office | 2023 | 49 | 55 | $27,335 | $10,966 | 40.1% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 70 | 74 | $90,946 | $5,932 | 6.5% |
| 78315 | Nuclear medicine study of bone taken at different times | Office | 2023 | 21 | 21 | $14,364 | $4,801 | 33.4% |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | Office | 2023 | 68 | 74 | $5,275 | $4,168 | 79.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Facility | 2023 | 284 | 284 | $11,928 | $2,584 | 21.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 44 | 44 | $10,384 | $2,511 | 24.2% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Facility | 2023 | 62 | 64 | $38,528 | $2,362 | 6.1% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Facility | 2023 | 41 | 47 | $9,956 | $1,392 | 14.0% |
| 78195 | Nuclear medicine study of lymphatic system | Facility | 2023 | 28 | 28 | $5,936 | $1,073 | 18.1% |
| 78608 | Nuclear medicine study of brain with metabolic evaluation | Facility | 2023 | 16 | 16 | $5,088 | $850.72 | 16.7% |
| 78582 | Nuclear medicine study of lung ventilation and circulation | Facility | 2023 | 20 | 20 | $3,387 | $770.84 | 22.8% |
| 78469 | Nuclear medicine study of heart muscle following heart attack with spect | Facility | 2023 | 20 | 20 | $2,700 | $661.40 | 24.5% |
| 78264 | Nuclear medicine study of stomach to assess emptying | Facility | 2023 | 18 | 19 | $3,401 | $517.45 | 15.2% |
| 78709 | Nuclear medicine studies of kidney, blood flow, and function | Facility | 2023 | 11 | 11 | $4,444 | $454.77 | 10.2% |
| 78226 | Nuclear medicine study of liver and bile duct system | Facility | 2023 | 13 | 15 | $1,758 | $420.27 | 23.9% |
| 78227 | Nuclear medicine study of liver and bile duct system with use of drugs | Facility | 2023 | 12 | 12 | $1,608 | $358.05 | 22.3% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2022 | 125 | 147 | $754,188 | $177,231 | 23.5% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2022 | 124 | 146 | $73,000 | $38,036 | 52.1% |
| 78306 | Nuclear medicine study of bone and/or joint whole body | Office | 2022 | 61 | 67 | $33,299 | $13,566 | 40.7% |
| 78315 | Nuclear medicine study of bone taken at different times | Office | 2022 | 23 | 23 | $15,732 | $5,503 | 35.0% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2022 | 45 | 46 | $56,534 | $3,878 | 6.9% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Facility | 2022 | 228 | 228 | $9,576 | $2,132 | 22.3% |
About Dr. Ping Lu, MD
Dr. Ping Lu, MD is a Nuclear Medicine healthcare provider based in Albany, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144393265.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ping Lu, MD has received a total of $1,240 in payments from pharmaceutical and medical device companies, with $370.83 received in 2024. These payments were reported across 20 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($1,240).
As a Medicare-enrolled provider, Lu has provided services to 4,167 Medicare beneficiaries, totaling 4,654 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 88 distinct procedure/service records.
Ad
Practice Information
- Specialty Nuclear Medicine
- Location Albany, NY
- Active Since 11/16/2006
- Last Updated 05/09/2024
- Taxonomy Code 207U00000X
- Entity Type Individual
- NPI Number 1144393265
Products in Payments
- THYROGEN (Drug) $233.11
- Xofigo (Drug) $119.89
- DISCOVERY (Device) $108.73
- DISEASE STATE (Drug) $96.59
- POSLUMA (Drug) $78.77
- LEXISCAN (Drug) $20.54
- Lexiscan (Drug) $20.05
- ENTRESTO (Drug) $20.00
- VYNDAQEL (Drug) $19.39
- ILLUCCIX (Drug) $18.51
- SPECT Symiba Intevo (Device) $15.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.